Annual Report 2003 - Parkway Pantai

More documents

Recommendations

Info

BUSINESS REVIEWWe make strategic investments in technology to support our specialists in providingour patients the latest treatment options, and, therefore, the best value.CENTRES OF EXCELLENCEOne of the cornerstones of our commitment tomedical excellence is the development ofmultidisciplinary centres for key specialties whichenable Parkway to offer the most advanced andsophisticated treatments in the region.These Centres of Excellence currently focus oncancer, liver, cardiac and neurology conditions.Parkway Cancer CentresDuring the year, Parkway made particular progressin developing its Cancer Centres at Gleneagles andMount Elizabeth Hospitals, which offer a comprehensiverange of oncology services, ranging fromdiagnosis to treatment and counselling.The Group has made significant capital investmentin cutting-edge equipment and facilities to maintainits lead in oncology services.Positron Emission Tomography -Computerised Tomography (PET-CT) ScannerConsistent with our focus on high value-addedservices, the Group invested almost S$5 million inthe highly sophisticated PET-CT scanner to providethis service to our cancer patients.From mid-July 2003, PET-CT scans were availableat Mount Elizabeth Hospital. The Hospital becamethe first private hospital in Singapore to offerPET-CT scans.PET-CT has been described as one of the top 10inventions of the century. This scanner enables datafusion from both the PET and CT, thus providinganother dimension to diagnostic imaging.The image from the PET-CT is based on the organs’physiological function while CT data is based purelyon anatomy. Data fusion of these two modalitiesprovides a quantum leap in diagnosis, makingPET-CT one of the most accurate and rapid meansof detecting and managing cancer and otherconditions which are otherwise impossible to detect.Recent developments have made PET-CT integralto the management of lung, colorectal, liver and braincancers, lymphomas, melanomas as well as epilepsyand coronary heart disease.Demand for PET-CT scan services will be fuelled bythe regional market.20 Parkway Holdings Limited Annual Report 2003
BUSINESS REVIEWMicro-multi-leaf collimator-based radiosurgeryThe Group has also recently added a specialisedoncology treatment to the extensive range ofservices offered at Gleneagles Cancer Centre.The multi-million equipment provides micro-multi-leafcollimator-based radiosurgery.BrainLab M3 micro-multi-leaf collimator-basedradiosurgery is one of the latest cancer treatmenttechniques that maximises irradiation to the tumourwhile minimising damage to healthy tissues, thusproviding cancer patients with significantimprovement in treatment outcomes.CanHOPEAs an extension of our oncology services, the Grouplaunched a free non-profit cancer counsellingservice, hotline and website, CanHOPE in August2003. Our professional counsellors offer cancerpatients emotional and psychosocial support, andassist them in making clear, informed decisions ontreatment options.Specialised Liver Intensive Care UnitBuilding upon our reputation for hepatobiliary andtransplant surgeries, the Group launched the LiverIntensive Care Unit at Gleneagles Hospital,Singapore, in October 2003.It is Asia’s onlydedicated ICU to serve the specialised needs ofpatients with acute liver failure (ALF).The Unit is fully equipped with sophisticateddiagnostic tools, monitoring devices, ventilators, liverand kidney dialysis machines and other equipment.It offers liver dialysis using the advanced MolecularAdsorbents Recirculating System (MARS).The Unit supplements the Group’s dedicatedoperating theatres for hepatobiliary and transplantsurgeries and state-of-the-art equipment for livingdonor liver transplant (LDLT).Serving both Parkway and non-Parkway patients,CanHOPE is an added resource to cancer patientsas well as our contribution to the community.Parkway Holdings Limited Annual Report 200321
Page 1 and 2: PASSION FORPEOPLE &PROGRESSPARKWAY
Page 3 and 4: ABOUT USParkway Holdings Limited is
Page 5 and 6: Apollo Gleneagles Hospital, Kolkata
Page 7 and 8: This is the essence of our ‘Integ
Page 9 and 10: As the dominant player in the Singa
Page 11 and 12: In Healthcare Services, the Group i
Page 13 and 14: Prospects Looking ForwardThe Manage
Page 15 and 16: 2003 FINANCIAL REVIEWGROUP CONSOLID
Page 17 and 18: FINANCIAL REVIEWHospital Statistics
Page 19 and 20: FINANCIAL REVIEWPROFIT AFTER TAX AN
Page 21: MEDICAL EXCELLENCEAs a leading inte
Page 25 and 26: BUSINESS REVIEWParkway Hospitals in
Page 27 and 28: QUALITY SERVICEQuality service is o
Page 29 and 30: BUSINESS REVIEWREGIONAL MEDICAL REF
Page 31 and 32: INVESTMENT IN EXPERTISEOur healthca
Page 33 and 34: Mr Ang Guan SengNon-executive Direc
Page 35 and 36: SENIOR MANAGEMENTDr Lim Cheok PengM
Page 37 and 38: CORPORATE OFFICEPARKWAY HOLDINGS LI
Page 39 and 40: FINANCIALS 2003Directors’ Report
Page 41 and 42: Directors’ Interests (Cont’d)Ho
Page 43 and 44: Share Options (Cont’d)Parkway Emp
Page 45 and 46: Share Options (Cont’d)Parkway Sha
Page 47 and 48: STATEMENT BY DIRECTORSYear ended 31
Page 49 and 50: BALANCE SHEETSas at 31 December 200
Page 51 and 52: CONSOLIDATED STATEMENT OF CHANGES I
Page 53 and 54: CONSOLIDATED STATEMENT OF CASH FLOW
Page 55 and 56: NOTES TO THE FINANCIAL STATEMENTS31
Page 57 and 58: 2. Summary of Significant Accountin
Page 63 and 64: LeaseholdOfficePremisesS$’000Reno
Page 65 and 66: 5. Interests in Subsidiaries - The
Page 73 and 74:
7. Interests in Partnerships - The
Page 75 and 76:
11. Inventories - The GroupInventor
Page 77 and 78:
17. Other Payables2003S$’000The G
Page 79 and 80:
18. Interest-Bearing Borrowings (Co
Page 81 and 82:
19. Employee Benefits - The Group (
Page 83 and 84:
No. of optionsexercisable at1 Jan 2
Page 85 and 86:
No. of optionsexercisable at1 Jan 2
Page 87 and 88:
22. Share Capital - The Company (Co
Page 89 and 90:
26. Directors’ Remuneration - The
Page 91 and 92:
29. Earnings Per Share (Cont’d)(a
Page 93 and 94:
31. Significant Related Party Trans
Page 95 and 96:
34. AssociatesName of AssociatePrin
Page 97 and 98:
34. Associates (Cont’d)Name of As
Page 99 and 100:
35. Financial Instruments (Cont’d
Page 101 and 102:
36. Segment Reporting (Cont’d)(a)
Page 103 and 104:
36. Segment Reporting (Cont’d)(b)
Page 105 and 106:
2. Interested Person TransactionsIn
Page 107 and 108:
4. Corporate Governance Statement (
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
ANALYSIS OF SHAREHOLDINGSas at 17 F
Page 121 and 122:
(b)That the Board of Directors of t
Page 123 and 124:
PROXY FORMPARKWAY HOLDINGS LIMITED(
Page 125 and 126:
CORPORATE OFFICEPARKWAY HOLDINGS LI
show all

Annual Report 2003 - Parkway Pantai

Create successful ePaper yourself

Delete template?

Save as template?